Most U.S. stocks go head over heels in the course of corporate results and a resume in crude’s selloff. Treasuries skimmed with gold and the dollar headed for the peak close in more than a decade on the visions for a hike in borrowing costs.
The Standard & Poor’s 500 Index lost 0.3 percent at 11:15 a.m. in New York, extending its first back-to-back monthly slide since May 2012.
The Dow Jones Industrial Average climbed 24 points, or 0.1%, to 17215, as McDonald’s Corp. rallied.
The main focus of this article is on such biotech sector companies, which are gaining the pace during their Thursday’s opening trade. The financial data along with latest news and profiles of respective companies are described underneath:
Tekmira Pharmaceuticals, (NASDAQ:TKMR), inclined 0.78% during last trading session, reaching $25.80. The stock has a 52 week low of $8.86 and a 52 week high of $31.48. So far this year, the stock is up over 68.71%.
Tekmira Pharmaceuticals Corp declared that it has dosed the first subject in a Phase I clinical trial of TKM-HBV, a therapeutic agent designed to reduce hepatitis B surface antigen in patients chronically infected with hepatitis B virus (HBV).
Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners.
ZIOPHARM Oncology, (NASDAQ:ZIOP), skyrocketed 5.92% during last trading session, reaching $8.92. The stock has a 52 week low of $2.31 and a 52 week high of $9.64. So far this year, the stock gained over 78.11%.
Intrexon Corporation (XON), and its oncology partner, ZIOPHARM Oncology (ZIOP), announced a broad exclusive licensing contract with The University of Texas MD Anderson Cancer Center, comprising an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the expansion of non-viral adoptive cellular cancer immunotherapies.
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the discovery and development of cancer therapies that address unmet medical needs through synthetic biology.
GenVec, (NASDAQ:GNVC), declined -3.50% during the recent trading session, touching $3.31. The stock has a 52 week low of $1.61 and a 52 week high of $4.12. So far this year, the stock inclined over 63.94%.
GenVec, Inc. operates as a biopharmaceutical company that uses differentiated and proprietary technologies to create therapeutics and vaccines.
Aldeyra Therapeutics, (NASDAQ:ALDX), enhances 1.38% during recent trading session, reaching $11.67. The stock has a 52 week low of $3.00 and a 52 week high of $13.50. So far this year, the stock is up over 64.68%.
The corporation announced that novel data on the potential of its lead product candidate, NS2, to treat Sjogren-Larsson Syndrome (SLS) has been accepted for a poster presentation at the upcoming 2015 Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held March 28-31, 2015 in Salt Lake City, Utah.
Aldeyra Therapeutics, Inc. develops drug candidates for capturing and removing free aldehydes to treat and prevent diseases, and slow the progression of chronic disease.
